VBI Vaccines
22 Third Street, Suite 2241
Cambridge
Massachusetts
02142
United States
Tel: 617-830-3031
Website: http://www.vbivaccines.com/
Email: info@vbivaccines.com
185 articles about VBI Vaccines
-
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
6/28/2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new data from a follow-up analysis of a subset of participants from the pivotal Phase 3 study (PROTECT) of the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine.
-
VBI Vaccines Announces Results of Annual General Meeting - June 22, 2022
6/22/2022
VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, announced the voting results from its annual general meeting of shareholders held on June 22, 2022.
-
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
6/22/2022
VBI Vaccines Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for VBI-1901, a bivalent gB/pp65 immunotherapeutic vaccine candidate for the treatment of glioblastoma (GBM).
-
VBI Vaccines and Hepion Pharmaceuticals have received Orphan Drug Designations from the U.S. Food and Drug Administration for their experimental cancer drugs.
-
VBI Vaccines to Participate in the Jefferies Healthcare Conference
6/7/2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022.
-
VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting
6/6/2022
Median overall survival and 18-month overall survival data continue to show improvements over historical controls 1.
-
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
6/1/2022
PreHevbri™ is the only approved 3-antigen hepatitis B vaccine for adults in the United Kingdom.
-
VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
5/26/2022
VBI Vaccines Inc. today announced that an abstract has been accepted for oral presentation at The International Liver Congress™ 2022 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place June 22-26, 2022.
-
VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022
5/19/2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that health economics and outcomes research (HEOR) comparing the cost-effectiveness of the Company’s 3-antigen hepatitis B vaccine (HBV), PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], to a single-antigen HBV vaccine, Engerix-B®, among adults.
-
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/9/2022
VBI Vaccines Inc. today announced financial results for the first quarter ending March 31, 2022 and provided a corporate update.
-
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
5/2/2022
VBI Vaccines Inc. today announced that the European Commission (EC) has granted Marketing Authorisation for PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] for active immunisation against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.
-
VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 2022 ASCO Annual Meeting
4/28/2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), today announced that tumor response and overall survival data from the ongoing Phase 2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), was accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program
4/5/2022
VBI Vaccines Inc. today announced updated clinical and preclinical data from its coronavirus program, VBI-2900.
-
VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
3/29/2022
VBI Vaccines Inc. today announced that PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] is now available in the United States for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults age 18 years and older.
-
VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference
3/15/2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the 32nd Annual Oppenheimer Healthcare Conference.
-
VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2021, Provides Corporate Update and Outlook for 2022
3/7/2022
VBI Vaccines Inc. today announced financial results for the fourth quarter and twelve months ended December 31, 2021.
-
VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union
2/25/2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion for VBI’s 3-antigen hepatitis B (HBV) vaccine, under the brand name PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)].
-
VBI Vaccines Announces PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults
2/23/2022
VBI Vaccines Inc. today announced that, following discussion at this afternoon’s meeting of the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] now joins the list of recommended products for prophylactic adult vaccination against hepatitis B (HBV) infection.
-
VBI Vaccines to Participate in the B. Riley Securities 2022 Oncology Investor Conference
1/26/2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that David E. Anderson, Ph.D, VBI’s Chief Scientific Officer, will present an overview of VBI-1901, the Company’s cancer immunotherapeutic for the treatment of glioblastoma (GBM), at B. Riley’s Oncology Investor Conference.
-
VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio
1/5/2022
VBI Vaccines Inc. today announced that the first patient has been dosed in a second Phase 2a/2b clinical study evaluating VBI-2601 (BRII-179), an immunotherapeutic candidate targeting chronic hepatitis B virus (HBV).